倍他索洛尔(betaxolol)是80年代初由法国Synthelabo公司研究开发的新型心脏选择性β阻滞剂。在心脏选择性β阻滞剂中,其半衰期最长,并能全部控制24小时的血压,其β阻滞作用的普萘洛尔的4倍,首过效应低、生物利用度高,临床上用于治疗高血压、缺血性心脏病、心律失常等,具有广阔的应用前景。它首先在法国、西德、英国等国上 Betaxolol is a novel cardioselective beta-blocker developed by Synthelabo in France in the early 1980s. Among the heart-selective β-blockers, they have the longest half-life and are capable of fully controlling blood pressure for 24 hours, 4 times more potent beta-blocker than propranolol, with a low first pass effect and high bioavailability, clinically For the treatment of hypertension, ischemic heart disease, arrhythmia, etc., has broad application prospects. It first in France, West Germany, Britain and other countries